Lupin posts strong Q1FY17

Lupin has declared its Q1FY17 results on Tuesday. The company’s revenue has increased by 40.66 per cent to Rs 4439 crore in Q1FY17 as compared to same period in previous financial year. Its EBITDA too has risen by 58.54 per cent to Rs 1308 crore in Q1FY17 on a yearly basis. Lupin’s EBITDA margin has expanded by 333 basis points to 29.47 per cent in Q1FY17 as compared to same period in previous fiscal year. The company’s net profit also has boosted by 74.16 per cent to Rs 973 crore in Q1FY17 on a yearly basis. Its net profit margin has expanded by 422 basis points to 21.92 per cent in Q1FY17 as compared to same period in previous financial year.

On the segmental revenue front, Lupin has earned 50.74 per cent from North America; 21.59 per cent from India; 12.56 per cent from Asia Pacific region; 5.09 per cent from Europe, Middle East and Africa; 2.52 per cent from Latin America; 0.85 per cent from rest of the world during Q1FY17. The company also has earned 6.65 per cent from API. 

The share price of Lupin has declined by 2.53 per cent on bourses in early trades; and is trading at Rs 1657.1 on an intraday basis.

Lupin is producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, Anti-Infective and NSAID space; and holds global leadership position in the Anti-TB segment.